Professor Ian Meredith (Melbourne, Australia) presented the 1-year results from the 100 patient strong ENDEAVOR I study. The ENDEAVOR I trial is a first-in-man, nonrandomized trial of 100 patients with de novo native coronary lesions, 3 to 3.5 mm diameter, treated with the ABT-578-coated stent. ABT-578 is a rapamycinlike analog developed by Abbott Laboratories, while the base stent, the Driver, is a cobalt-alloy device.

Professor Meredith reported that the Endeavor stent achieved favorable results a TVF rate of 2.0 percent at nine and 12 months, a TLR rate of 1.0 percent at nine and 12 months, and in-stent late lumen loss at 12 months of 0.58 mm. In-segment late lumen loss at 12 months was 0.40 mm. The TVF, TLR and Major Adverse Cardiac Events (MACE) rate, (2.0 percent at 12 months), remained unchanged from their previous four-month analysis, meaning that there were no clinical events beyond the four-month period. Additional 12-month data included an Angiographic Binary Restenosis rate of 3.3 percent and a Percent Volume Obstruction of 9.7 percent at 12 months.